Table 1 Demographic and clinical characteristics of study participants
| Â | Whole Abs | Galcanezumab | Fremanezumab | Erenumab | p value |
|---|---|---|---|---|---|
Number of patients | 68 | 31 | 24 | 13 | - |
M/F | 10/58 | 1/30 | 5/19 | 4/9 | 0.0839 |
Age, years | 46.2 ± 13.1 | 43.8 ± 11.5 | 48.5 ± 15.6 | 47.9 ± 11.4 | 0.5733 |
Age of onset, years | 24.6 ± 11.4 | 21.4 ± 8.5 | 29.4 ± 15.2 | 30.0 ± 11.7 | 0.0539 |
Disease duration, years | 22.0 ± 11.1 | 22.2 ± 11.1 | 20.1 ± 10.0 | 25.3 ± 13.4 | 0.617 |
MO/MA | 60/8 | 29/2 | 21/3 | 10/3 | 0.4829 |
Baseline MMDs | 13.3 ± 6.0 | 14.0 ± 5.9 | 12.9 ± 5.5 | 12.9 ± 7.0 | 0.9108 |
CM diagnosis, n (%) | 27.9 | 29.0 | 33.3 | 30.8 | 0.9818 |
Medication overuse, n (%) | 14.7 | 19.4 | 4.7 | 7.7 | 0.361 |
Baseline HIT-6 score | 66.7 ± 5.6 | 66.9 ± 5.9 | 67.2 ± 5.5 | 65.5 ± 5.8 | 0.8481 |
Number of previously used preventive drug classes, n (%) | |||||
 1 | 35 | 16 | 12 | 7 | 0.9827 |
 2 | 20 | 8 | 8 | 4 | 0.9038 |
 3 | 8 | 4 | 3 | 1 | 0.9779 |
  ≥ 4 | 3 | 3 | 0 | 0 | 0.3145 |
Comcomitant use of preventive drug(s) | 42 | 18 | 16 | 8 | 0.9352 |
GAD-7 scorea | 6.9 ± 5.3 | 5.7 ± 4.7 | 7.8 ± 5.6 | 8.6 ± 6.5 | 0.7157 |
PHQ-9 scorea | 6.8 ± 5.3 | 4.7 ± 3.0 | 8.1 ± 5.6 | 10.0 ± 7.1 | 0.2413 |
Complications | |||||
 Hypertension, n (%) | 11.8 | 16.1 | 8.3 | 7.7 | 0.7895 |
 Diabetes mellitus, n (%) | 1.5 | 0 | 14.7 | 0 | 0.6018 |
 Dyslipidemia, n (%) | 8.8 | 9.6 | 8.3 | 7.7 | 0.9965 |